Gemma Salvadó

6.0k total citations · 5 hit papers
59 papers, 1.5k citations indexed

About

Gemma Salvadó is a scholar working on Psychiatry and Mental health, Physiology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Gemma Salvadó has authored 59 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Psychiatry and Mental health, 37 papers in Physiology and 13 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Gemma Salvadó's work include Dementia and Cognitive Impairment Research (43 papers), Alzheimer's disease research and treatments (35 papers) and Functional Brain Connectivity Studies (10 papers). Gemma Salvadó is often cited by papers focused on Dementia and Cognitive Impairment Research (43 papers), Alzheimer's disease research and treatments (35 papers) and Functional Brain Connectivity Studies (10 papers). Gemma Salvadó collaborates with scholars based in Spain, Sweden and United Kingdom. Gemma Salvadó's co-authors include Juan Domingo Gispert, Kaj Blennow, José Luís Molinuevo, Henrik Zetterberg, Marc Suárez‐Calvet, Oskar Hansson, Oriol Grau‐Rivera, Karine Fauria, Rik Ossenkoppele and Frederik Barkhof and has published in prestigious journals such as Nature Medicine, Nature Neuroscience and Journal of the American College of Cardiology.

In The Last Decade

Gemma Salvadó

54 papers receiving 1.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers

2023 150 citations Niklas Mattsson, Gemma Salvadó et al. JAMA Neurology profile →
Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads

2023 92 citations Gemma Salvadó, Rik Ossenkoppele et al. EMBO Molecular Medicine profile →
Disease staging of Alzheimer’s disease using a CSF-based biomarker model

2024 49 citations Gemma Salvadó, Kanta Horie et al. Nature Aging profile →
Plasma Phosphorylated Tau 217 and Aβ42/40 to Predict Early Brain Aβ Accumulation in People Without Cognitive Impairment

2024 42 citations Shorena Janelidze, Nicolas R. Barthélemy et al. JAMA Neurology profile →
Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s disease

2025 27 citations Kanta Horie, Gemma Salvadó et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gemma Salvadó Spain	22	805	767	271	268	223	59	1.5k
Tobey J. Betthauser United States	23	844 1.0×	956 1.2×	198 0.7×	299 1.1×	228 1.0×	97	1.7k
Stephanie J. B. Vos Netherlands	21	982 1.2×	1.1k 1.4×	280 1.0×	276 1.0×	122 0.5×	44	1.7k
Argonde C. van Harten Netherlands	19	807 1.0×	1.1k 1.4×	269 1.0×	311 1.2×	100 0.4×	68	1.6k
Daniele Altomare Switzerland	18	694 0.9×	725 0.9×	315 1.2×	376 1.4×	330 1.5×	52	1.7k
Meredith N. Braskie United States	28	768 1.0×	676 0.9×	265 1.0×	638 2.4×	407 1.8×	79	2.0k
Emily S. Lundt United States	22	560 0.7×	727 0.9×	167 0.6×	417 1.6×	217 1.0×	45	1.2k
Alex C. Birdsill United States	15	819 1.0×	470 0.6×	296 1.1×	290 1.1×	401 1.8×	28	1.8k
Alexandra J. Weigand United States	22	396 0.5×	682 0.9×	239 0.9×	318 1.2×	131 0.6×	65	1.2k
Kok Pin Ng Singapore	17	557 0.7×	544 0.7×	236 0.9×	204 0.8×	177 0.8×	77	1.1k
J‐Sebastian Muehlboeck Sweden	22	712 0.9×	1.0k 1.3×	486 1.8×	623 2.3×	378 1.7×	41	1.8k

Countries citing papers authored by Gemma Salvadó

Since Specialization

Citations

This map shows the geographic impact of Gemma Salvadó's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gemma Salvadó with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gemma Salvadó more than expected).

Fields of papers citing papers by Gemma Salvadó

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gemma Salvadó. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gemma Salvadó. The network helps show where Gemma Salvadó may publish in the future.

Co-authorship network of co-authors of Gemma Salvadó

This figure shows the co-authorship network connecting the top 25 collaborators of Gemma Salvadó. A scholar is included among the top collaborators of Gemma Salvadó based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gemma Salvadó. Gemma Salvadó is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cicognola, Claudia, Gemma Salvadó, Ruben Smith, et al.. (2025). APOE4 impact on soluble and insoluble tau pathology is mostly influenced by amyloid-β. Brain. 148(7). 2373–2383. 3 indexed citations

Suárez‐Calvet, Marc, Marta Milà‐Alomà, Juan Domingo Gispert, et al.. (2025). Longitudinal Associations of Multimodal Core 1 Alzheimer Disease Biomarkers With Cognition in Aging and Preclinical Alzheimer Disease. Neurology. 105(9). e214308–e214308. 1 indexed citations

Andersson, Emelie, Shorena Janelidze, Gemma Salvadó, et al.. (2025). Soluble cerebral Aβ protofibrils link Aβ plaque pathology to changes in CSF Aβ42/Aβ40 ratios, neurofilament light and tau in Alzheimer’s disease model mice. Nature Aging. 5(3). 366–375. 11 indexed citations

Montoliu‐Gaya, Laia, Gemma Salvadó, Joseph Therriault, et al.. (2025). Plasma tau biomarkers for biological staging of Alzheimer’s disease. Nature Aging. 5(11). 2297–2308.

Ottoy, Julie, Murat Bilgel, Alexa Pichet Binette, et al.. (2025). Recent advances in neuroimaging of Alzheimer's disease and related dementias. Alzheimer s & Dementia. 21(9). e70648–e70648. 3 indexed citations

Palmqvist, Sebastian, Gemma Salvadó, Niklas Mattsson, et al.. (2024). Evaluation of the prospective use of blood biomarkers for Alzheimer’s disease in primary and secondary care. Alzheimer s & Dementia. 20(S2).

Lantero‐Rodriguez, Juan, Gemma Salvadó, Anniina Snellman, et al.. (2024). Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer’s Disease. Molecular Neurodegeneration. 19(1). 19–19. 13 indexed citations

Bali, Divya, Shorena Janelidze, Gemma Salvadó, et al.. (2024). Comparison of plasma ALZpath p‐Tau217 with Lilly p‐Tau217 and p‐Tau181. Alzheimer s & Dementia. 20(S2).

Salvadó, Gemma, Kanta Horie, Nicolas R. Barthélemy, et al.. (2024). Disease staging of Alzheimer’s disease using a CSF-based biomarker model. Nature Aging. 4(5). 694–708. 49 indexed citations breakdown →

10.

Salvadó, Gemma, Victoria Larsson, Karly Alex Cody, et al.. (2023). Optimal combinations of CSF biomarkers for predicting cognitive decline and clinical conversion in cognitively unimpaired participants and mild cognitive impairment patients: A multi‐cohort study. Alzheimer s & Dementia. 19(7). 2943–2955. 24 indexed citations

11.

Mattsson, Niklas, Gemma Salvadó, Nicholas J. Ashton, et al.. (2023). Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers. JAMA Neurology. 80(4). 360–360. 150 indexed citations breakdown →

12.

Salvadó, Gemma, Kanta Horie, Nicolas R. Barthélemy, et al.. (2023). Novel CSF tau biomarkers can be used for disease staging of sporadic Alzheimer’s. Alzheimer s & Dementia. 19(S14). 1 indexed citations

13.

Barthélemy, Nicolas R., Benjamin Saef, Yan Li, et al.. (2023). CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease. Nature Aging. 3(4). 391–401. 67 indexed citations

14.

Pemberton, Hugh, Lyduine E. Collij, Fiona Heeman, et al.. (2022). Quantification of amyloid PET for future clinical use: a state-of-the-art review. European Journal of Nuclear Medicine and Molecular Imaging. 49(10). 3508–3528. 104 indexed citations

15.

Salvadó, Gemma, et al.. (2021). Differential associations of APOE-epsilon 2 and APOE-epsilon 4 alleles with PET-measured amyloid-beta and tau deposition in older individuals without dementia. UCL Discovery (University College London). 2 indexed citations

16.

Alves, Isadora Lopes, Fiona Heeman, Lyduine E. Collij, et al.. (2021). Strategies to reduce sample sizes in Alzheimer’s disease primary and secondary prevention trials using longitudinal amyloid PET imaging. Alzheimer s Research & Therapy. 13(1). 82–82. 15 indexed citations

17.

Lantero‐Rodriguez, Juan, Anniina Snellman, Andréa L. Benedet, et al.. (2021). P‐tau235: a novel biomarker for staging preclinical Alzheimer’s disease. EMBO Molecular Medicine. 13(12). e15098–e15098. 30 indexed citations

18.

Cortés‐Canteli, Marta, Juan Domingo Gispert, Gemma Salvadó, et al.. (2021). Subclinical Atherosclerosis and Brain Metabolism in Middle-Aged Individuals. Journal of the American College of Cardiology. 77(7). 888–898. 34 indexed citations

19.

Salvadó, Gemma, Anna Brugulat‐Serrat, Carole H. Sudre, et al.. (2019). Spatial patterns of white matter hyperintensities associated with Alzheimer’s disease risk factors in a cognitively healthy middle-aged cohort. Alzheimer s Research & Therapy. 11(1). 12–12. 53 indexed citations

20.

Brugulat‐Serrat, Anna, Gemma Salvadó, Carole H. Sudre, et al.. (2019). Patterns of white matter hyperintensities associated with cognition in middle-aged cognitively healthy individuals. Brain Imaging and Behavior. 14(5). 2012–2023. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact